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BACKGROUND: Previous studies have suggested an association between subclinical hypothyroidism and coronary
artery disease that could be related to changes in serum lipids or endothelial dysfunction.
METHODS: Thirty-two female subclinical hypothyroidism patients were randomly assigned to 12 months of L-
thyroxine replacement or no treatment. Endothelial function was measured by the flow-mediated vasodilatation of
the brachial artery, as well as mean carotid artery intima-media thickness, and lipid profiles were studied at baseline
and after 12 months of follow-up.
RESULTS: The mean (¡SD) serum thyroid-stimulating hormone levels in the L-thyroxine replacement and control
groups were 6.09¡1.32 and 6.27¡1.39 mUI/ml, respectively. No relationship between carotid artery intima-media
thickness or brachial flow-mediated vasodilatation and free T4 and serum thyroid-stimulating hormone was found.
The median L-T4 dose was 44.23¡18.13 mg/day. After 12 months, there was a significant decrease in the flow-
mediated vasodilatation in the subclinical hypothyroidism control group (before: 17.33¡7.88 to after: 13.1¡4.75%,
p=0.03), but there were no significant differences in flow-mediated vasodilatation in the L-thyroxine treated group
(before: 16.81¡7.0 to after: 18.52¡7.44%, p=0.39). We did not find any significant change in mean carotid intima-
media thickness after 12 months of L-thyroxine treatment.
CONCLUSION: Replacement therapy prevents a decline in flow-mediated vasodilatation with continuation of the
subclinical hypothyroidism state. Large prospective multicenter placebo-controlled trials are necessary to investigate
endothelial physiology further in subclinical hypothyroidism patients and to define the role of L-thyroxine therapy
in improving endothelial function in these patients.
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INTRODUCTION
Subclinical hypothyroidism (SHT) is a disorder character-
ized by elevated serum thyroid-stimulating hormone (TSH)
levels despite normal free thyroid hormone values.1 The
prevalence of SHT ranges from 5 to 10%, and the condition
affects 6 to 10% of women (approximately 15% of women
over 60 years of age) and 2.4 to 3% of the male population.2,3
A recent meta-analysis demonstrated that SHT can lead to
an increased risk of developing cardiovascular disease and,
consequently, elevate cardiovascular-associated mortality,
especially in patients under 65 years of age.4-6 However,
different authors propose that this higher risk does not
apply to all patients with SHT, especially when the serum
TSH is only slightly elevated and there are no other
associated cardiovascular risks.7 It is unclear whether the
association between SHT and coronary artery disease is
related to SHT-induced changes in serum lipid levels.8-10 In
a population-based survey, SHT emerged as a significant
risk factor for aortic atherosclerosis and myocardial infarc-
tion in elderly women independently of serum cholesterol
level.11 Therefore, further studies should clarify the role of
SHT in cardiovascular disease.
The endothelium plays a major role in the maintenance of
vascular function and integrity through the production of
vasodilator and vasoconstrictor substances.12,13 Endothelial
dysfunction that results in reduced availability of nitric
oxide is an early marker of atherosclerosis and can be used
to predict coronary artery disease before the development of
atherosclerotic changes.14 Recent studies have shown that
hypothyroidism and SHT may have adverse effects on
endothelial function independently of other well-known
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atherosclerotic risk factors.15-22 Considerable controversy
surrounds the hypothesis that SHT has a significant effect
on the risk profile of cardiovascular disease. Boekholdt
et al.23 provided important information that addressed this
issue. Although higher elevated LDL cholesterol levels were
found in the SHT group, thyroid dysfunction was not linked
with a significantly increased risk of coronary heart disease.
Despite the association between thyroid hormone levels and
cardiovascular risk factors, thyroid status was not statisti-
cally significantly associated with the risk of future coronary
heart disease or all-cause mortality in that large cohort over
a follow-up of 10.6 years. The endothelial physiology in SHT
and the role of levothyroxine (L-T4) therapy in improving
endothelial function are still uncertain.
We previously reported no differences in flow-mediated
vasodilatation (FMD) of the brachial artery and carotid
artery intima-media thickness (IMT) in a group of women
with mild SHT without previously diagnosed cardiovascu-
lar disease compared with euthyroid subjects.24,25
The aims of the present study were to assess the effect of
L-T4 replacement on endothelial function measured by
FMD of the brachial artery, as well as carotid artery IMT in a
group of female patients with mild SHT.
PATIENTS AND METHODS
The study was a randomized open-label prospective trial
comparing the use of L-T4 in female patients with mild
SHT. Thirty-two women with mild SHT were recruited from
the Outpatient Clinic of the Clementino Fraga Filho
University Hospital (HUCFF), Federal University of Rio de
Janeiro (UFRJ). The inclusion criteria were at least two
documented laboratory determinations of SHT conducted at
least six weeks apart, as defined by both elevated TSH
(.4.0 mIU/ml) and normal free thyroxine (FT4) levels. The
patients had no previous history of thyroid disease. The
maximum TSH value accepted was 12 mIU/ml. This cutoff
represents three times the superior acceptable limit of the
TSH level, which is 4 mIU/ml. Individuals were excluded
from the study if they had a history of alcohol use or were
suffering from any cardiovascular disease or concomitant
non-thyroid illnesses (e.g., obesity, diabetes mellitus, arterial
hypertension, liver, or renal diseases). We examined their
personal histories, physical examinations, and laboratory
tests. The routine laboratory test included kidney function
tests (urea, creatinine), liver function tests (ALT, AST, and
GGT), and mean glycemia.
The routine laboratory chemistry was normal in all
patients, and no patient was taking any drug that could
interfere with thyroid, lipoprotein, or endothelial function.
The drugs that could interfere included amiodarone,
corticosteroids, estrogens, lithium, statins, diuretics, and
fibrates; additional drugs were used to treat diabetes,
arterial hypertension, or obesity. The patients had no history
of recent hospitalization. Patients with SHT were randomly
allocated to treatment with L-T4 (levothyroxine group) or
no treatment (observation group). Fixed-block numbers
were used to generate the random allocation sequence of
the treatment group. Each patient received a number in a
block of four or six random numbers. Each number
corresponded to one of the follow-up groups (levothyroxine
group or observation group). Blocks of six and four
numbers were continuously distributed, and each block
had half of the numbers corresponding to treatment and
another half corresponding to observation. For those
patients who were treated, the initial L-T4 dose was
0.75 mg/kg/day. Patients were re-evaluated every four
weeks based on the clinical evaluation (including diet
habits and physical activity) and TSH and FT4 levels to
adjust the dose. The dose that achieved a normal serum TSH
was subsequently maintained. After a normal TSH level was
obtained, patients were seen every three months to assess
the presence of adverse effects, disease progression, and
whether the L-T4 dose needed adjustment. The patients in
the observation group (OG) were re-evaluated every four
weeks, and blood tests were used to measure TSH and FT4
levels.
All patients were instructed to reduce the fat in their daily
diet. The patients received general recommendations of a
healthy diet, including the following: consume fish, espe-
cially oily fish, at least twice a week; limit the intake of
saturated fat and trans fat by choosing lean meats and
vegetable alternatives, as well as fat-free or low-fat dairy
products and minimizing the intake of partially hydro-
genated fats; minimize the intake of beverages and foods
with added sugars; and choose and prepare foods with little
or no salt. These recommendations were written and
provided to all patients.
A re-evaluation of serum lipids, FMD and carotid IMT
was performed one year after the restoration of the
euthyroidism state or one year after inclusion in the group
of patients with SHT who did not receive L-T4 treatment.
The subjects did not use any lipid-lowering medications
during the study.
The study was approved by the UFRJ Institutional Ethics
Committee, and all subjects provided written informed
consent to participate. The number of the protocol for the
Ethics Committee in Research was 12-01.
A general physical examination was performed, including
assessment of height (without shoes), weight, and waist
circumference (the minimum value between the iliac crest
and the lateral costal margin). BMI was calculated as the
weight (kg) divided by the height squared (m2). Systolic and
diastolic blood pressures were measured from the right
brachial artery of the subjects in a supine position after 10
min of rest using a pneumatic sphygmomanometer.
Venous blood samples were drawn between 8:00 and 9:00
am after a 12-hour overnight fast. Serum was centrifuged
and stored at -80 C˚ until assayed. Serum TSH, FT4 and
thyroid peroxidase antibody (TPO-Ab), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-c), trigly-
ceride (TG), apoprotein B (apoB), apoprotein A (apoA), and
lipoprotein a [Lp(a)] levels were determined in both groups.
Serum TSH, FT4 and TPO-Ab were measured by immu-
nochemiluminescence (Immulite 2000; DPC, Diagnostic
Products Corporation, USA). Reference ranges for TSH and
FT4 were 0.4-4.0 mIU/ml and 0.8-1.9 ng/dl, respectively.
TPO-Ab levels of .35 IU/ml were considered positive. The
intra-assay coefficients of variation were 3.8-12.5, 4.4-7.5, and
4.3-5.6% for TSH, FT4, and TPO-Ab, respectively. The inter-
assay coefficients of variation were 4.6-12.5, 4.8-9.0, and 7.8-
10.5%, respectively. TC and TG (Vitros Chemistry Products,
USA), as well as HDL-c (Boehringer Mannheim Systems,
Germany), were determined enzymatically. Low-density
lipoprotein cholesterol (LDL-c) was calculated by the
Friedewald equation: LDL-c = (TC – HDL-c) - (TG/5). The
reference ranges for TC, HDL-c, TG, and LDL-c were based
on the Adult Treatment Panel III of the National Cholesterol
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Education Program (NCEP).26 The Lp(a) concentration was
determined by an immunoradiometric assay (Diagnosis
System International, Novatech, USA) and apoA and apoB
were measured by a rate nephelometric immunoassay
(Beckman Coulter, USA), and their reference ranges were
lower than 30, 90-200, and 30-100 mg/dl, respectively.
The subjects were investigated by high-resolution color-
Doppler ultrasound imaging (Toshiba Nemium, Japan; 14-
mHz linear probe) of the brachial artery in the dominant
arm. The study was performed in a temperature-controlled
room (25 C˚) with subjects resting in the supine position. The
blood pressure and heart rate were recorded on the opposite
arm every three min using an automatic sphygmoman-
ometer. The subjects’ dominant arm was comfortably
immobilized in the extended position to allow consistent
access to the brachial artery. Doppler ultrasound measure-
ments were performed before and 60 seconds after reactive
hyperemia (RH). To avoid interobserver variability, all
measurements were performed by the same examiner,
who was blinded to the subjects’ clinical status. Brachial
artery vasodilation in response to RH was determined by a
previously validated technique.27,28 The intraclass correla-
tion coefficient of this technique has been reported
previously by our laboratory and ranges from R=0.7001 to
R= 0.8420 (p,0.05).29,30 The scans were recorded on S-VHS
videotape. The internal diameter of the brachial artery was
assessed at the end of diastole, and the arterial flow was
measured using the pulse Doppler sample volume at an
angle of 60˚ or less in the center of the artery. For each
subject, optimal brachial artery images were obtained
approximately 5 cm above the antecubital fossa. Arm
pressure was generating by inflating a pneumatic arm band
above the elbow cuff to a pressure up to 30 mmHg higher
than the subject’s systolic arterial pressure for 5 min. The
cuff was then deflated, the arterial flow was immediately
recorded and the diameter was measured 60 to 90 seconds
after deflation. For both diameters, one measurement was
recorded. FMD was calculated according to the following
formula: FMD = (post-occlusion diameter - baseline
diameter)6100/baseline diameter.
The carotid images were obtained with the patient in the
supine position with the neck mildly extended and the head
rotated contralaterally to the side. The imaging protocol
involved obtaining a minimum of four longitudinal B-mode
images of the distal 10 mm of the right and left common
arteries and the carotid bifurcation. The whole image
session was recorded on videotape. The IMT of the common
carotid artery (CCA) and carotid bifurcation were calculated
by the same examiner with high-resolution ultrasound
imaging (Acuson Aspen Advanced, 10 mHz linear probe,
USA), as previously described.31 The final analysis was
performed with IMT images of both the near and far wall of
the right and left common artery and the carotid bifurcation.
The recordings were evaluated by the same reader, who was
blinded to the clinical data. The diastolic frames of each
carotid segment were digitized. Lines were drawn along the
lumen-intimal and medial adventitial interfaces in all
analyzed segments, and the IMT of each segment was
automatically computed as an average of several measure-
ments. For statistical analysis, IMT readings in all the
carotid segments were averaged (mean IMT). Plaque was
considered as a focal structure if it encroached into the
arterial lumen by at least 0.5 mm or 50% of the surrounding
IMT value or demonstrated a thickness .2.0 mm, as
measured from the media-adventitia interface to the
intima-lumen interface. The reproducibility of the IMT
measurement was acceptable, as demonstrated by coeffi-
cients of variation of 7.7¡4.3%.31
Statistical analysis
A statistical analysis was performed using SPSS for
Windows, version 10.0. The mean values of the numerical
variables were compared between groups by the Mann-
Whitney test if they were not normally distributed, as
detected by the Kolmogorov-Smirnov Liliefors test.
Parametric variables were compared by the Student t-test.
Data were expressed as means ¡ SD values unless
otherwise stated. We also determined the frequencies of
qualitative variables. For multi-group comparisons, one-
way analysis of variance (ANOVA) or the Kruskal-Wallis
test was applied, as appropriate. Analysis of frequencies
was performed with the use of contingency tables (chi-
square test). Correlations between parameters were tested
by Pearson or Spearman correlation coefficients. The
variation in the studied variables for each SHT patient
who completed the follow-up protocol was calculated. The
effect of LT-4 was assessed by comparing the mean
variations between the two SHT groups (treated and
observational), based on a per-protocol approach. The
different effects of L-T4 replacement were also assessed by
comparing the means before and after intervention by the
Wilcoxon Signed Rank Test or Student’s t-test. A p value of
,0.05 was considered to be significant.
RESULTS
Thirty-two female patients with mild SHT without
previously treated thyroid or vascular disease were ran-
domly assigned to 12 months of L-T4 replacement or no
treatment and were evaluated. 14 patients were randomly
assigned to the L-T4 treatment group (LtG), and 18 patients
were randomly assigned to the observational group (OG).
During the study, no patient was excluded. Both groups
were similar with respect to age, BMI, waist circumference,
activity level, smoking behavior, menopausal status, and
laboratory and vascular parameters.
Baseline data:
Table 1 shows the baseline information of the patients in
the different studied groups. All patients had spontaneous
and primary hypothyroidism, and the majority had positive
circulating TPOAb (Table 1). No relationship between
carotid IMT or brachial FMD and free T4 and TSH was
found.
Follow-up data:
TSH and FT4 levels at the end of the study (12 months)
are shown in Table 2. No significant changes were observed
in BMI and waist circumference (data not shown) or in other
laboratory variables (Table 2). The median dose of L-T4 was
44.23¡18.13 mg/day.
As shown in Figure 1, there was a significant decrease in
the brachial artery FMD after 12 months in the OG (p= 0.03)
and no significant difference in FMD in the LtG (p=0.39).
We did not find any correlation between the carotid IMT
and the studied variables or a reduction of carotid IMT after
one year of LT4 treatment (Table 2). We found plaques in 2
patients in each group, and there was no difference after one
year of treatment.
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When comparing the mean changes during the study in
the two TPO-Ab patients within the prospective SHT
groups, no significant differences in brachial artery FMD
were found (LtG, 1.13¡9.5; OG -5.58¡9.59; p= 0.12).
When the patients in each group were subdivided into
low ($4 but ,8 mIU/ml) or high ($8 but ,12 mIU/ml) TSH
levels, no differences were observed in metabolic or
vascular parameters (data not shown).
A stratified analysis that considered the presence of any
type of dyslipidemia based on NCEP criteria was per-
formed. Dyslipidemia was defined as elevated TC, elevated
triglycerides, elevated LDL-c and/or decreased HDL-c.
There was a non-significant decrease in FMD in the OG in
both subgroups (dyslipidemia present or absent) and a non-
significant increase in FMD in the LtG in both subgroups.
Changes in brachial FMD and carotid artery IMT after one
year of follow-up in the LtG and OG based on the presence
or absence of dyslipidemia are shown in Table 3.
DISCUSSION
LT-4 treatment did not significantly improve endothelial
function or reduce the carotid IMT in subjects with mild
SHT who were similar with respect to age, BMI, smoking,
menopausal status, and endothelial function modifiers.
After one year, there was a significant decrease in brachial
artery FMD in the OG and no difference in LtG, which
suggests that thyroid hormone replacement could prevent a
decline in FMD in patients with SHT. The exclusion of
participants with concomitant hormonal, renal, or liver
diseases allowed us to control our analysis for confounding
variables and yielded a homogeneous population. In
addition, by excluding co-morbid conditions, the mean
age was reduced, allowing a smaller sample size for the
study.
Few studies have evaluated carotid IMT and the effect of
L-T4 replacement in subclinical thyroid dysfunction.
Monzani et al.15 were the first to show higher mean IMT
values in SHT patients compared with age- and sex-
matched controls. The maximal thickness in any particular
segment was also measured (maximal IMT) and was higher
in the SHT group. We previously reported no significant
differences in the mean carotid IMT in a group of subclinical
hypothyroid patients compared with a euthyroid group,
which suggests that mild SHT is not associated with an
increase in cardiovascular risk when assessed by carotid
IMT.24,25 Monzani et al.25 were also the first to evaluate the
benefit of six months of L-T4 replacement therapy on IMT in
patients with SHT. L-T4 significantly reduced both LDL-c
and the mean IMT, suggesting that lipid infiltration of the
arterial wall may represent the main mechanism underlying
the increase in IMT in patients with SHT. In the present
work, we did not find any association between carotid IMT
Table 1 - Baseline data of levothyroxine-treated and
observation groups.
OG LtG
Age (yr) 47.59¡8.4 43.36¡9.8
BMI (kg/m2) 26.24¡2.71 25.89¡2.29
Waist (cm) 84.06¡8 83.17¡6.5
Sedentary behavior (%) 94.4 85.7
Smokers (%) 11.1 14.3
Menopause (%) 55.6 50
HRT (%) 0 0
Familial dyslipidemia (%) 33.3 34.4
TSH (mUI/ml) 6.77¡1.96 6.79¡2.0
FT4 (ng/dl) 0.95¡0.15 0.97¡0.13
TPO-Ab (%) 61.1 64.3
TC (mg/dl) 226.11¡43.55 213.43¡53.17
HDL-c (mg/dl) 51.83¡10.28 56.78¡11.15
LDL-c (mg/dl) 147.5¡37.58 137.92¡47.94
TG (mg/dl) 132.5¡50.82 136.07¡119.18
Lipoprotein(a) (mg/dl) 53.83¡62.87 61.78¡62.71
ApoB (mg/dl) 128.61¡34.16 109.28¡44.15
ApoA (mg/dl) 148.83¡24.73 150.21¡24.73
Mean IMT (mm) 0.65¡0.23 0.66¡0.11
Flow-mediated dilatation
(%)
17.33¡7.88 16.81¡7.0
Notes: Values are expressed as means ¡ SD or frequency. The p values
were .0.05.
OG, observation group; LtG, levothyroxine group; HRT, hormone
replacement treatment; TSH, thyroid-stimulating hormone; FT4, free
thyroxine; TPO-Ab, antiperoxidase antibody; TG, triglycerides; HDL-c,
high-density lipoprotein cholesterol; TC, total cholesterol; LDL-c, low-
density lipoprotein cholesterol; apoA, apoprotein A; apo B, apoprotein B;
IMT, intima-media thickness; FMD, flow-mediated vasodilatation.
Table 2 - Initial (baseline) and final (after one year) results of the levothyroxine-treated and observation groups.
Observation group Levothyroxine Group
Baseline 1 year Baseline 1 year
TSH (mUI/ml) 6.77¡1.96b
(4.2-11.0)
6.69¡3,51b,
(3.27-13.5)
6.79¡2.0a,b
(4.04-10.65)
3.02¡0.89a,b
(1.54-4.0)
FT4 (ng/dl) 0.95¡0.15 1.06¡0.15 0.97¡0.13 1.16¡0.18
TC (mg/dl) 226.11¡43.55 227.6¡36.9 213.43¡53.1 208.4¡36.7
HDL-c (mg/dl) 51.83¡10.28 49.61¡9.74 56.78¡11.15 54.36¡12.3
LDL-c (mg/dl) 147.5¡37.58 150.6¡34.74 137.92¡47.94 132.8¡37.5
TG (mg/dl) 132.5¡50.82 137.0¡56.06 136.07¡119.18 106.0¡36.7
Lipoprotein (a) (mg/dl) 53.83¡62.87 48.21¡47.22 61.78¡62.71 58.87¡64.09
ApoB (mg/dl) 128.61¡34.16 125.94¡27.47 109.28¡44.15 105.1¡27.17
ApoA (mg/dl) 148.83¡24.73 136.78¡24.04 150.21¡24.73 144.14¡25.57
Mean IMT (mm) 0.65¡0.23 0,67¡0,18 0.66¡0.11 0.66¡0.15
FMD (%) 17.33¡7.88a,b 13.10¡4.75a,b 16.81¡7.0 b 18.52¡7.44 b
Values are expressed as means ¡ SD; TSH values are expressed as the mean ¡ SD (interquartile range).
ap,0.05 comparing before and after values within each group.
bp,0.05 comparing the mean changes between the two prospective SHT groups during the study.
For all other values, p.0.05.
TSH, thyroid-stimulating hormone; FT4, free thyroxine; TG, triglycerides; HDL-c, high-density lipoprotein cholesterol; TC, total cholesterol; LDL-c, low-
density lipoprotein cholesterol; apoA, apoprotein A; apoB, apoprotein B; IMT, intima-media thickness; FMD, flow-mediated vasodilatation.
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and the variables studied. Furthermore, no reduction of
carotid IMT was appreciated after one year of L-T4 therapy.
The cardiovascular system is a specific target of thyroid
hormones (THs); thus, thyroid dysfunction is accompanied
by profound changes in cardiovascular hemodynamics.26,27
Both the vasculature and the endothelium play pivotal roles
in modulating vascular tone, and both are potential targets
of THs.28 Several studies have demonstrated the presence
of thyroid receptors in endothelial cells.32,33 Some studies
have suggested a role for vascular smooth muscle (VSM)
cells in mediating the vasodilating effect of T3 infusion in
the endothelium in human euthyroid subjects.34,35
Little is known about the interaction of TSH with
endothelial cells. The TSH receptor is present in the thyroid
gland and, also, in many other sites, such as VSM cells.34
Dardano et al. demonstrated that an acute systemic increase
of serum TSH levels by rhTSH injection induced a significant
impairment of endothelial vasodilatation in conduit arteries.
Few studies have evaluated the relationship between SHT
and endothelial dysfunction and the effect of L-T4 replace-
ment in the endothelial function of subclinical hypothyroid
patients. Lekakis et al.17 were the first to describe the negative
association between borderline and mild hypothyroidism
and FMD. In their study, cholesterol did not differ
significantly among groups but tended to be higher in the
hypothyroidism and SHT groups, and the authors concluded
that higher cholesterol levels may be associated with
endothelial dysfunction. Dagre et al.36 noninvasively
assessed the NO-dependent endothelial function of resis-
tance arteries in subjects with hypothyroidism of varying
severity by measuring the forearm blood flow response
during reactive hyperemia via utilizing venous occlusion
strain-gauge plethysmography. Endothelial dysfunction was
only detected in the microvasculature of patients with overt
hypothyroidism. We previously reported no significant
differences in brachial FMD in a group of subclinical
hypothyroid patients compared with a euthyroid group,
which suggests that mild thyroid dysfunction had no adverse
effects on endothelial function in the population studied.24
Taddei et al.22 showed in a group of subclinical hypothyroid
patients that 6 months of euthyroidism by L-T4 replacement
increased acetylcholine-induced vasodilation. They also
observed a significant correlation between the maximal
response to acetylcholine and changes in LDL-c. In a
randomized, double-blind, crossover study of L-T4 or
placebo for 12 weeks, brachial FMD was significantly
improved in the group of patients who took a daily dose of
100 mg of L-T4 compared with the placebo group.
Multivariate analysis showed that increased serum FT4
levels were the most significant variable predicting a
reduction in TC or improvement in FMD.23 Xiang et al.
showed that TSH, FT3 (free T3), LDL-c and Lp(a) levels were
Table 3 - Changes in brachial FMD and mean EIM after one year of follow-up in the L-T4 group and the observation
group based on the presence or absence of dyslipidemia.
Dyslipidemia present Dyslipidemia absent
Group OG LtG OG LtG
Mean IMT (mm) 0.00¡0.01 0.00¡0.01 0.00¡0.01 0.00¡0.01
Flow-mediated dilatation (%) -3.84¡5.97 1.15¡7.95 -5.0¡11.7 2.46¡8.62
Values are expressed as the mean changes between the two prospective SHT groups through the study. All other p.0.05.
OG, observation group; LtG, levothyroxine group; FMD, flow-mediated vasodilatation; IMT, intima-media thickness.
Figure 1 - Changes in FMD% in the levothyroxine-treated and observation groups.
CLINICS 2011;66(8):1321-1327 Effects of thyroxine replacement
Cabral MD et al.
1325
significant factors associated with endothelium-dependent
arterial dilation in Hashimoto’s thyroiditis patients with
euthyroidism.35 The lack of FT3 measurement is a limitation
of our study and is also important for ruling out the possible
inclusion of subjects with non-thyroidal illness syndrome.
The interpretation of the results strongly depends on the
effectiveness of substitutive treatment. According to the
literature,7 in this case, the optimal values for TSH in L-T4
treated patients are unclear. As shown in some studies, it is
not uncommon for patients in clinical trials to be outside of
the therapeutic target at the end of the study. Ravzi et al.6
demonstrated a significant improvement in cardiovascular
risk factors in a group of patients with SHT treated by LT-4,
and 27 patients had discordant thyroid function tests during
the course of the study.
This study was a randomized open-labeled prospective
trial. A double-blind, placebo-controlled study would be a
more suitable approach. Another limitation of this study
was the small sample size, which makes it difficult to obtain
a clear decision about the benefit of L-T4 treatment in SHT
patients. More studies with larger patient populations are
needed to elucidate this subject more fully.
We did not measure the maximal IMT during the internal
carotid artery measurements, which could be considered a
limitation of the study. An important issue is which IMT
measure (e.g., mean IMT value; maximal IMT value;
internal carotid artery from the anterior, lateral, and
posterior angle; and composite measures from the left and
right side or from different arterial sides) should be used.
There is no definite answer to this question, but, for study
purposes, all segments should be analyzed.
The brachial artery vasodilation in response to RH was
determined by FMD of the brachial artery. FMD is an indirect
way of measuring the endothelial function using vascular
reactivity. We did not assess endothelium-independent
vasodilatation, which could be assessedwith a dose-response
curve to sodium nitroprusside. While it is important to
perform nitrate dilatation to confirm that the findings were
not due to media disease, as opposed to endothelial
dysfunction, we were unable to perform this evaluation
and suggest that it be performed in future works. Some
studies that assessed the response to sodium nitroprusside
(which specifically acts on smooth muscle cells) have shown
similar responses in both groups (control and SHT groups)
and a reduced vasodilatory effect of acetylcholine in SHT
patients; these results indicate that SHT is characterized by
the presence of endothelial dysfunction.17,22
Another limitation of this study is that we did not
measure estradiol levels or the duration of menopause. This
finding is important because abnormal FMD values can be
obtained in older women and women who experienced a
long menopausal period. Although both groups were
similar in relation to age, the control group was more than
four years older than the treated one; thus, the changes in
FMD could be related to the development of climacterium.
In the present study, the reportedmean values for TSH after
treatment were in the upper limit of the normal range. Some
patients were under-treated, and this finding could explain
why we did not find a significant benefit after LT-4 treatment.
CONCLUSION
Our data suggest that thyroid hormone replacement
therapy could prevent a decline in FMDwith the continuation
of the SHT state in comparison with untreated subjects. Large,
prospective, multicenter placebo-controlled trials are neces-
sary to further investigate the endothelial physiology of
patients with SHT and to define the role of L-T4 therapy in
improving endothelial function in patients with SHT.
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